Business Context and Reporting Period
This Form 6-K filing by GSK plc, a global biopharma company, was issued on June 1, 2026. The report serves as a notification to the market regarding the Company's issued share capital and total voting rights as of May 31, 2026, in conformity with the Financial Conduct Authority's Disclosure Guidance and Transparency Rule 5.6.1R.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a corporate governance notification regarding share capital rather than a financial performance report.
| Metric | Value |
|---|---|
| Issued Share Capital (as of May 31, 2026) | 4,316,224,814 Ordinary Shares (31.5 pence each) |
| Treasury Shares | 265,968,706 |
| Total Voting Rights | 4,050,256,108 |
Material Changes
The filing text does not provide a clear value for material changes versus a prior comparable period. The document focuses solely on the current state of share capital and voting rights.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document contains a brief corporate purpose statement but no strategic or risk-related disclosures.
Important Facts for Investors to Verify
- Confirm the total number of voting rights (4,050,256,108) to determine if notification thresholds under FCA rules have been met.
- Verify the number of shares held in Treasury (265,968,706) when calculating free float or ownership percentages.
- Note that this filing does not contain financial performance data; refer to Form 20-F or quarterly earnings releases for revenue and profit metrics.